Synlogic (SYBX)
(Delayed Data from NSDQ)
$1.44 USD
+0.03 (1.77%)
Updated Sep 13, 2024 09:52 AM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Brokerage Reports
Synlogic, Inc. [SYBX]
Reports for Purchase
Showing records 81 - 100 ( 111 total )
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Fireside Chat; SYNB1020 Preclinical and Phase 1 Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
SYNB1891 Slated to Enter Clinical Testing Next Year; 3Q18 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Key Clinical Data Coming in Mid 19 Across the Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Liver Meeting Data Adds Value; SITC Update Shows Pipeline Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Leadership Situation Clarified; Further Clinical Milestones Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Initial Safety and PD Data Validates PKU Program
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
SYNB1618 Demonstrates Activity in Interim Clinical Data Among Healthy Volunteers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Financial Results Reported; Looking Ahead to Trial Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Additional Preclinical Data Presentations; Russell 3000 Index Inclusion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
SYNB1020 Preclinical Data Presented During Digestive Disease Week; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
1Q 2018 Financial Results Reported; Lower-Than-Projected R-D Spending; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
1Q, Thesis Intact Despite Sudden Departure of CEO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Chief Executive Officer Steps Down; Disruption Unlikely; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
Granting of FT Reaffirms Favorable Regulatory Outlook for Synthetic Biotics
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Synlogic, Inc.
Industry: Medical - Biomedical and Genetics
First Subject Dosed in SYNB1618 Phase 1/2a Trial in Phenylketonuria; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R